Showing results (91-100 of 302) with videos related to
Sort By:
Pageof 31
Cancers|June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg StudyHenner Stege, Maximilian Haist, Michael Schultheis, et al.European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG studyLea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.Cancer Immunology, Immunotherapy : CII|October 9, 2017
Safety of shortened infusion times for combined ipilimumab and nivolumabMaximilian Gassenmaier, Hans-Peter Lipp, Alexander Scheu, et al.European Journal of Cancer (Oxford, England : 1990)|June 16, 2018
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeLaura Milsch, Anja Gesierich, Sophia Kreft, et al.Frontiers in Oncology|December 2, 2020
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case ReportJohanna Matull, Elisabeth Livingstone, Axel Wetter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.British Journal of Pharmacology|March 11, 2026
Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio-oncology RegistryElias Haj-Yehia, Lisa Zimmer, Lena Lampe, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 14, 2020
Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknessesMaja Ann Hofmann, Ulrike Keim, Agata Jagoda, et al.Pageof 31